Evidence map›Paper›PMID 32202644›Full record

ArticleJAMA network open2020

Assessment of Thyroid Function in Patients With Alkaptonuria.

Shirisha Avadhanula, Wendy J Introne, Sungyoung Auh, Steven J Soldin, Brian Stolze, Debra Regier, Carla Ciccone, Fady Hannah-Shmouni, Armando C Filie, Kenneth D Burman and 1 more

Open access · goldAbstract readEvaluation Study
In one paragraph

Article in JAMA network open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Alkaptonuria.Nature reviews. Disease primers · 2024
    Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 1 country.

Shirisha AvadhanulaNational Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.
Wendy J IntroneNational Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland.
Sungyoung AuhNational Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.
Steven J SoldinDepartment of Laboratory Medicine, National Institutes of Health, Bethesda, Maryland.
Brian StolzeNational Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland.
Debra RegierChildren's National Rare Disease Institute, Children's National Medical Center, Washington, DC.
Carla CicconeNational Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland.
Fady Hannah-ShmouniNational Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland.
Armando C FilieNational Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Kenneth D BurmanEndocrine Section, Medstar Washington Hospital Center, Washington, DC.
Joanna Klubo-GwiezdzinskaNational Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.
National Institutes of Health · USEunice Kennedy Shriver National Institute of Child Health and Human Development · USNational Human Genome Research Institute · USChildren's National · USMedStar Washington Hospital Center · USNational Cancer Institute · USNational Institute of Diabetes and Digestive and Kidney Diseases · US

Funding

Human Biochemical GeneticsZIAHG000215 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI GAHL, WILLIAM · 2009 to 2025
$72.6M
Cytopathology CoreZICBC011052 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI FILIE, ARMANDO · 2009 to 2025
$30.8M
Studies of Thyroid Function in Health and DiseaseZIEDK075005 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI KLUBO-GWIEZDZINSKA, JOANNA · 2013 to 2024
$2.3M
Role of Mass Spectrometry in Improving the Diagnosis of Endocrine DisordersZIACL010355 · CLC · CLINICAL CENTER · PI SOLDIN, STEVEN · 2014 to 2020
$0k
6 · The paper itself

Abstract

Importance: Alkaptonuria is an autosomal recessive disorder caused by pathogenic variants in the HGD gene. Deficiency of the HGD enzyme leads to tissue deposition of homogentisic acid (HGA), causing severe osteoarthropathies and cardiac valve degeneration. Although HGD is vital for the catabolism of tyrosine, which provides the basis for thyroid hormone synthesis, the prevalence of thyroid dysfunction in alkaptonuria is unknown. Objective: To assess thyroid structure and function in patients with alkaptonuria. Design, Setting, and Participants: A single-center cohort study was conducted in a tertiary referral center including patients with alkaptonuria followed up for a median of 93 (interquartile range, 48-150) months between February 1, 2000, and December 31, 2018. The alkaptonuria diagnosis was based on clinical presentation and elevated urine HGA levels. A total of 130 patients were considered for participation. Main Outcomes and Measures: Prevalence of thyroid dysfunction in adults with alkaptonuria compared with the general population. Thyrotropin and free thyroxine levels were measured by immunoassay and repeated in each patient a median of 3 (interquartile range, 2-22) times. Neck ultrasonographic scans were analyzed in a subset of participants. Logistic regression was used to test the association of thyroid dysfunction with age, sex, thyroid peroxidase (TPO) antibodies, serum tyrosine levels, and urine HGA levels. Results: Of the 130 patients, 5 were excluded owing to thyroidectomy as the cause of hypothyroidism. The study cohort consisted of 125 patients; the median age was 45 (interquartile range, 35-51) years. Most of the patients were men (72 [57.6%]). The prevalence of primary hyperthyroidism was 0.8% (1 of 125 patients), similar to 0.5% observed in the general population (difference, 0.003; 95% CI, -0.001 to 0.04; P = .88). The prevalence of primary hypothyroidism was 16.0% (20 of 125 patients), which is significantly higher than 3.7% reported in the general population (difference, 0.12; 95% CI, 0.10-0.24; P < .001). Women were more likely to have primary hypothyroidism than men (odds ratio, 10.99; 95% CI, 3.13-38.66; P < .001). Patients with TPO antibodies had a higher likelihood of primary hypothyroidism than those without TPO antibodies (odds ratio, 7.36; 95% CI, 1.89-28.62; P = .004). There was no significant difference in the prevalence of thyroid nodules between patients in this study (29 of 49 [59.2%]) vs the general population (68%) (difference, 0.088; 95% CI, -0.44 to 0.73; P = .20) or of cancer (7% vs 5%; difference, 0.01; 95% CI, -0.01 to 0.17; P = .86). Conclusions and Relevance: The high prevalence of primary hypothyroidism noted in patients with alkaptonuria in this study suggests that serial screening in this population should be considered and prioritized.

Indexed as

AdultAlkaptonuriaAutoantibodiesAutoantigensCohort StudiesFemaleHomogentisic AcidHumansHyperthyroidismHypothyroidismIodide PeroxidaseIron-Binding ProteinsLogistic ModelsMaleMiddle AgedPrevalenceAutoantibodiesAutoantigensHomogentisic AcidIodide PeroxidaseIron-Binding ProteinsThyrotropinThyroxineTPO protein, humanTyrosine

Identifiers

PMID32202644
PMCPMC7090965
OpenAlexW3012925268

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.